Limited availability of structurally diverse natural product derivatives restricts the discovery of potent therapeutic agents. Expanding accessible chemical space overcomes bottlenecks in drug lead identification.

Unregulated ferroptosis and viral-induced cellular stress lead to tissue degradation. Mitigating these specific failure modes prevents systemic organ dysfunction and disease progression.

Chemical scaffolds like pyrazolopyrimidines and myricetin derivatives are modified to overcome low binding affinity or poor therapeutic efficacy. Enhancing potency reduces required dosage and improves clinical outcomes.

Current therapeutic options for leukemia suffer from insufficient efficacy or drug resistance. Developing new molecular scaffolds targets these underlying biological failures to improve patient survival rates.

Limited availability of diverse chemical scaffolds restricts the discovery of potent therapeutic agents. Expanding the library of bioactive compounds overcomes structural limitations in current drug leads.